Navigation Links
Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
Date:6/18/2013

NESS ZIONA, Israel, June 18, 2013 /PRNewswire/ --

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for Tapentadol. Tapentadol is indicated in the US and Europe for the oral treatment of moderate-to-severe acute pain.

US Patent number 8,410,176 B2 is titled Intermediate Compounds and Processes for the Preparation of Tapentadol and Related Compounds. Mapi's innovative process enables the company to obtain Tapentadol in an optically active pure form.  The process is cost effective, uses easily available reagents and fits scalable industrial processes.

Tapentadol is indicated for the relief of moderate-to-severe acute pain. This segment of pain relievers has continuously grown during the last decade as a result of improved delivery technologies, increased physician recognition of the need for effective pain treatment, and the rising requirement for pain medication by the growing ageing population.  

"The patent acceptance announced today is Mapi's second in just one month. The first was for a long acting depot formulation of Glatiramer Acetate for the treatment of MS. Both patents strengthen Mapi's patent position, support the business plan and advance the company one step closer to bringing patients improved medications at affordable prices," said Mapi Pharma President & CEO Mr. Ehud Marom. "The pain relief market requires a specific expertise in dealing with potent pharmaceuticals. Mapi is uniquely positioned to answer the growing needs of this market."

The moderate-to-severe acute pain relief market i
'/>"/>

SOURCE Mapi Pharma Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. WuXi PharmaTech Announces Third-Quarter 2011 Results
3. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Fiscal Year End 2011 Financial Results
5. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. PRA Expert to Present at Pharmacovigilance Conference
8. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
9. InnoPharma Completes $15 Million Series A Financing
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. ViroPharma to Participate in Two December Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, today ... the Sidoti & Company Emerging Growth Conference on September ... at the New York Marriott Marquis. ... through the investor relations section of Roka Bioscience,s website ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... , ... August 26, 2015 , ... PRC Clinical, ... develop new business relationships with local sponsors in southern California. The Clinical Trial Management ... drug development processes and regulatory pathways., , Stem Cell ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Multiple Ultrasound Solution Provider Doubles Sales Over Same Period Last ... ... WAUKESHA, Wis., Aug. 27 MedPro Imaging, a premier,provider of ... representing a doubling of sales,over the same period last year. Recent ...
... Following the successful acquisition of,Drug Development Solutions (,DDS,) ... today that it has fully,integrated its two early ... Early Phase., Chiltern Early Phase is providing ... via its two well established units in Slough,(just ...
... Inc. (Nasdaq: AMLN ) and Eli Lilly and ... provided context and additional information,regarding the August 18, 2008 ... alert for BYETTA(R) (exenatide) injection referencing,pancreatitis. The companies were ... well as others, and previously reported these cases to ...
Cached Biology Technology:MedPro Installs 1000th Ultrasound System Worldwide 2Chiltern Early Phase: Fully Integrated and Business Ready 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/31/2015)... July 31, 2015 The 10 th International ... by BGI from October 22-25, 2015, in Shenzhen ... conference is celebrating its 10 th anniversary this year. Since ... world,s most influential annual meetings in the ,omics, fields, and ... gatherings. ICG-10 focuses on recent breakthroughs and ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... cancer as a major cause of death among children ... adequately addressed by national or international health organizations and ... Hospital. This growing rate of pediatric cancer is occurring ... is being reduced through the efforts of the World ...
... prices at the gas pump could come in the ... biomass, according to a joint feasibility study for the ... Oak Ridge National Laboratory report outlines a national strategy ... organic matter that is available on a renewable or ...
... everything was big has helped Queensland researchers to unearth ... responsible for wiping out Australian giant marsupials or megafauna ... specimens' such as giant kangaroos and wombats, the researchers ... performed the first systematic analysis of a site in ...
Cached Biology News:Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 2Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 3Human Cells Filmed Instantly Messaging for First Time 2Small species back-up giant marsupial climate change extinction claim 2Small species back-up giant marsupial climate change extinction claim 3
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: